Venrock Adviser, LLC

Position in OCUL — Ocular Therapeutix, Inc

CIK 1615982 NEW YORK, NY

Position in OCUL

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$87,638,463

-$1,172,277 QoQ

Shares Held

10,346,926

+41.4% QoQ

Ownership

4.73%

of shares outstanding

% of Portfolio

3.27%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. OCUL ranks #8 (3.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	8,493,321	$714,882,828
2	ERAS	Erasca, Inc.	16,382,812	$265,073,898
3	ORKA	Oruka Therapeutics, Inc.	4,148,428	$203,480,393
4	SYRE	Spyre Therapeutics, Inc.	3,685,448	$185,893,997
5	KALV	KalVista Pharmaceuticals, Inc.	6,474,485	$130,331,383
6	DNTH	Dianthus Therapeutics, Inc. /DE/	1,180,000	$99,025,600
7	DMRA	Damora Therapeutics, Inc.	3,603,595	$93,333,110
8	OCUL	Ocular Therapeutix, Inc This page	10,346,926	$87,638,463

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$87,638,463	10,346,926	+41.4%	Shares	Sole	2026-05-15
2025-12-31	$88,810,740	7,315,547	-44.4%	Shares	Sole	2026-02-17
2025-09-30	$153,857,490	13,161,462	+3.1%	Shares	Sole	2025-11-14
2025-06-30	$118,435,647	12,762,462	0.0%	Shares	Sole	2025-08-14
2025-03-31	$93,548,846	12,762,462	0.0%	Shares	Sole	2025-05-15
2024-12-31	$108,991,425	12,762,462	0.0%	Shares	Sole	2025-02-14
2024-09-30	$111,033,419	12,762,462	0.0%	Shares	Sole	2024-11-14
2024-06-30	$87,295,240	12,762,462	0.0%	Shares	Sole	2024-08-14
2024-03-31	$116,138,404	12,762,462	+64.1%	Shares	Sole	2024-05-15
2023-12-31	$34,679,889	7,775,760	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.